Partnership Engine Leverage past M&A and in license activity by GSK and AstraZeneca to position Sierra for out-licensing or co development deals around momelotinib and SRA737; target top oncology players to accelerate commercialization.

Market Readiness With Fast Track designation for momelotinib and funds allocated for commercial readiness, there is a clear need for market access planning, pricing strategy, payer engagement, and patient support programs.

Regulatory Expertise Regulatory leadership change alongside a proven U S and European approvals track creates opportunities for regulatory advisory services, territory strategy, and post approval compliance.

Clinical Partnerships Robust late stage pipeline and combination potential with PD-L1 inhibitors open avenues for CRO partnerships, trial design optimization, biomarker development, and manufacturing scale up.

Financing Pathways Existing funding and strategic finance relationships position Sierra for milestone based financing, co development investments, or selective debt facilities to support clinical and commercial milestones.